Overview
Pharmacokinetic Drug-Drug Interaction Study
Status:
Completed
Completed
Trial end date:
2015-01-01
2015-01-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The purpose of this study is to determine whether benznidazole and E1224 should be administered concomitantly in patients with Chagas Disease as not enough data are available. This study aims to assess cross interactions of these two compounds.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Drugs for Neglected DiseasesCollaborator:
PHINC DEVELOPMENTTreatments:
Benzonidazole
Criteria
Inclusion Criteria:1. Male healthy volunteers 18 to 45 years of age;
2. Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers;
3. Male subjects with a body weight of at least 50 kg and a body mass index (BMI)
calculated as weight in kg/height (in m2) from 18 to 28 kg/m2 at screening;
4. Able to communicate well with the Investigator and research staff and to comply with
the requirements of the entire study;
5. Provision of written informed consent to participate as shown by a signature on the
volunteer consent form;
Exclusion Criteria:
1. Who on direct questioning and physical examination have evidence of any clinically
significant acute or chronic disease, including known or suspected HIV, hepatites B
virus (HBV) or hepatites C virus (HCV) infection;
2. Who has positive diagnosis of T. cruzi infection indicated by Conventional serology;
3. With any clinically significant abnormality following review of pre-study laboratory
tests, vital signs, full physical examination and 12-lead ECG;
4. Who forfeit their freedom by administrative or legal award or who were under
guardianship;
5. Unwilling to give their informed consent;
6. Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or
anti-HIV 1/2 or anti- HCV antibodies;
7. Who have a history of allergy (serious or not), allergic skin rash, asthma,
intolerance, sensitivity or photosensitivity to any drug;
8. Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per
week, one unit = 8 g or about 10 mL of pure alcohol);